1. Home
  2. ELME vs SLN Comparison

ELME vs SLN Comparison

Compare ELME & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elme Communities

ELME

Elme Communities

N/A

Current Price

$2.15

Market Cap

198.2M

Sector

Real Estate

ML Signal

N/A

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

N/A

Current Price

$6.91

Market Cap

236.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ELME
SLN
Founded
1960
1994
Country
United States
United Kingdom
Employees
N/A
116
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
198.2M
236.2M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
ELME
SLN
Price
$2.15
$6.91
Analyst Decision
Hold
Buy
Analyst Count
3
5
Target Price
$12.67
$42.60
AVG Volume (30 Days)
1.1M
195.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
33.65%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$206,360,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.10
$1.97
52 Week High
$17.68
$7.78

Technical Indicators

Market Signals
Indicator
ELME
SLN
Relative Strength Index (RSI) 13.05 73.07
Support Level $2.10 $5.79
Resistance Level $2.26 $7.40
Average True Range (ATR) 0.03 0.57
MACD 0.24 0.18
Stochastic Oscillator 34.93 97.90

Price Performance

Historical Comparison
ELME
SLN

About ELME Elme Communities

Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: